Related Experiment Videos
Abstract:
Amgen has boosted its portfolio of cancer-targeted bispecific antibodies with the purchase of Teneobio for $900 million-plus as much as $1.6 billion more for meeting certain developmental milestones. The acquisition includes a potential treatment for prostate cancer and several other products.